RBC analyst says in-vitro diagnostics market grew 7.5% in Q2

By Lisa Kerner

Charlotte, N.C., Sept. 8 - The worldwide in-vitro diagnostics market grew 7.5% in constant currency to $7.1 billion in the second-quarter 2006 boosted by several key segments, according to a report by RBC Capital Markets analyst William R. Quirk.

The strongest segment, STD/Infectious Disease Testing, increased 27.3% to $140 million, led by Digene and Gen-Probe.

Market leader Gen-Probe, up 23%, took market share from Roche in the growing NAT blood screening segment, up 13.3% also to $140 million.

The still-strong Molecular Diagnostics market rose 18.4% to $605 million.

Quirk estimated the Central Lab Diagnostics (general chemistry, immunochemistry, hematology, coagulation and microbiology) increased 5.4% to $4.7 billion, while General Chemistry sales were up 3.7% at $1.5 billion.

Other segments that saw an increase include Diabetes Testing market, up 9.5% to $1.9 billion, worldwide Immunochemistry sales, up 7.4% to $2.0 billion, worldwide Hematology and revenue up 2.7% to $390 million.

Blood Banking growth was moderate, up 6.2% and Molecular Diagnostics growth remained strong, with sales at $605 million.

RBC said Blood Screening increased an estimated 13.3% and worldwide Viral Load Testing rose 12.8%.

Genetic Testing increased an estimated 26.1% to $185 million, with Genomic Health gaining the largest dollar share.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.